Jul. 11 at 12:58 PM
Just to update: I’ve exited my
$SLDB position for now.
As I outlined in my detailed breakdown in June, the early data remains encouraging, but this next phase is where the thesis truly gets stress-tested. As enrollment scales, real-world variability, immune responses, and patient heterogeneity begin to emerge. That’s always been the inflection point in programs like this... and it’s where I tend to manage risk deliberately.
Recent developments -- a second patient death in
$SRPT's program and a CRL for
$CAPR -- may seem independent on the surface, but to me, they reinforce a broader reality: gene therapy in DMD is under heightened regulatory scrutiny. In my view, these headlines aren’t bullish; they’re reminders that even well-structured programs are facing a much higher bar, especially under the current FDA regime. And events like accelerated approval are far from guaranteed.
I’m still very constructive on the science and the platform. But I’ve seen this movie before... and I know when a story starts moving from controlled early signals to the messy realities of broader execution. With the stock up 125% off the lows, that transition is well underway. The trial is just now expanding beyond ultra-small cohorts, and this next leg is where we’ll see whether early signals translate into consistent outcomes.
As always, I’ll continue to track developments closely and reassess as the story matures, but for now, I’m stepping aside and letting the next wave of data do the talking.
Cheers, and GLTA.
